Consumer medicine information

Caspofungin AN

Caspofungin

BRAND INFORMATION

Brand name

Caspofungin AN

Active ingredient

Caspofungin

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Caspofungin AN.

SUMMARY CMI

CASPOFUNGIN AN

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I given Caspofungin AN?

Caspofungin AN contains the active ingredient caspofungin acetate. Caspofungin AN is used to treat the following fungal infections: invasive candidiasis, including candidaemia; oesophageal candidiasis; invasive aspergillosis, when other antifungal treatments have not worked or when other antifungal treatments have not been tolerated.

For more information, see Section 1. Why am I given Caspofungin AN? in the full CMI.

2. What should I know before I am given Caspofungin AN?

Do not use if you have ever had an allergic reaction to caspofungin acetate or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I am given Caspofungin AN? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with Caspofungin AN and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How will I be given Caspofungin AN?

Caspofungin AN is given as a slow injection into the vein by a doctor or nurse. Your doctor will decide your dose and for how long. This may depend on your condition or other factors such as your liver function.

More instructions can be found in Section 4. How will I be given Caspofungin AN? in the full CMI.

5. What should I know when given Caspofungin AN?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using Caspofungin AN.
Driving or using machines
  • Be careful before you drive or use any machines or tools until you know how Caspofungin AN affects you.
Looking after your medicine
  • Caspofungin AN will be stored appropriately in the pharmacy or ward of a clinic or hospital.
  • It is kept in a refrigerator where the temperature stays between 2-8°C.

For more information, see Section 5. What should I know when given Caspofungin AN? in the full CMI.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention. This includes: Fever that has developed or worsened after starting treatment with Caspofungin AN, Signs of anaemia; Skin rash or itching; Difficulty breathing, shortness of breath or faster rate of breathing than usual; Swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing; Fast heart rate; Numbness or tingling in fingers or toes; Skin peeling, mucous membrane sores, large areas of peeling skin.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

CASPOFUNGIN AN

Active ingredient: Caspofungin Acetate

Consumer Medicine Information (CMI)

This leaflet provides important information about using Caspofungin AN. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Caspofungin AN.

Where to find information in this leaflet:

1. Why am I given Caspofungin AN?
2. What should I know before I am given Caspofungin AN?
3. What if I am taking other medicines?
4. How will I be given Caspofungin AN?
5. What should I know while I am given Caspofungin AN?
6. Are there any side effects?
7. Product details

1. Why am I given Caspofungin AN?

Caspofungin AN contains the active ingredient caspofungin acetate. Caspofungin AN belongs to a group of medicines called echinocandins.

It works by interfering with the production of a component of the fungal cell wall that is necessary for the fungus to continue living and growing. Fungal cells exposed to Caspofungin AN have incomplete or defective cell walls, making them fragile and unable to grow.

Caspofungin AN is used to treat the following fungal infections:

  • Invasive candidiasis, including candidaemia
  • Oesophageal candidiasis
  • Invasive aspergillosis, when other antifungal treatments have not worked or when other antifungal treatments have not been tolerated.

Also, your doctor may suspect that you have a fungal infection in the following situation, and prescribe Caspofungin AN to treat it.

  • Chemotherapy or other medical treatments or conditions can lower the body's resistance to disease by lowering counts of certain white blood cells. If you have persistent fever following chemotherapy or under other conditions as noted above, and your fever is not reduced by treatment with an antibiotic, you may have a fungal infection.

Candidiasis is an infection caused by a fungus (yeast) called candida.

Invasive candidiasis is a serious type of candidiasis which occurs in your bloodstream (referred to as candidaemia), or in tissues or organs such as the lining of the abdomen (peritonitis), the heart, kidneys, liver, bones, muscles, joints, spleen, or eyes.

Candidiasis can also occur in your food pipe, also known as the oesophagus (oesophageal candidiasis). It may cause difficulty or pain when swallowing.

Invasive aspergillosis is an infection caused by a fungus, called aspergillus (as-pur-jilus). Most of these infections begin in the respiratory tract (in the nose, sinuses, or lungs) because the spores of the fungus are usually present in the air we breathe. The spores are harmless in most healthy people due to the body's natural ability to fight disease.

However, invasive aspergillosis can be serious in certain circumstances as it can spread to other tissues and organs. Groups of people who are at increased risk of invasive aspergillosis include those who have poor immune systems, such as people with organ transplants, certain cancers and HIV/AIDS.

Your doctor may also have prescribed Caspofungin AN for another reason.

Ask your doctor if you have any questions about why Caspofungin AN has been prescribed for you.

The safety and effectiveness of Caspofungin AN in children or teenagers younger than 18 years of age have not been established.

2. What should I know before I am given Caspofungin AN?

Warnings

Do not use Caspofungin AN if:

  • If you have an allergy to caspofungin acetate or any of the ingredients listed at the end of this leaflet.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Before you are given Caspofungin AN

Tell your doctor if:

  1. you are pregnant
Like most medicines, Caspofungin AN is generally not recommended during pregnancy. However, if there is a need to consider using Caspofungin AN during pregnancy, your doctor will discuss the possible risks and benefits to you and your unborn baby.
  1. you have or have had any medical conditions, especially liver disease
  2. if you have any allergies to any other medicines or any other substances, such as foods, preservatives or dyes.

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Caspofungin AN is not recommended during pregnancy, however, if there is a need to consider using Caspofungin AN during pregnancy, your doctor will discuss the possible risks and benefits to you and your unborn baby.

Do not use Caspofungin AN if you are breastfeeding or intend to breastfeed.

Caspofungin AN is not recommended for use while breast feeding, it is not known whether it passes into breast milk in humans.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with Caspofungin AN and affect how it works.

These include:

  • Tacrolimus, used to help prevent organ transplant rejection or to treat certain problems with the immune system
  • Efavirenz and nevirapine, used to treat HIV infection
  • Phenytoin and carbamazepine, used to treat epilepsy and/or convulsions
  • Rifampicin, an antibiotic used to treat tuberculosis and other infections
  • Dexamethasone, a corticosteroid medicine used to treat inflammation.

These medicines may be affected by Caspofungin AN, or may affect how well it works. You may need different amounts of your medicine, or you may need to take different medicines.

Caspofungin AN should be used with caution with cyclosporin (a medicine used to help prevent organ transplant rejection or to treat certain problems with the immune system) as the combination may cause abnormalities in some tests of your liver function. In addition, using the two medicines together may increase the level of Caspofungin AN in your body.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect Caspofungin AN.

4. How will I be given Caspofungin AN?

How Caspofungin AN given

Caspofungin AN is given as a slow injection into a vein by a doctor or nurse.

Your doctor or nurse will decide what dose and for how long. This may depend on your condition and other factors such as your liver function. No dose adjustment is necessary if you are elderly or if you have reduced kidney function.

If you receive too much Caspofungin AN

Caspofungin AN will be given to you by a doctor or nurse, the likelihood of an overdose is very unlikely.

However, if you do think that you have been given too much Caspofungin AN, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while I am given Caspofungin AN?

Things you should do

Remind any doctor, dentist or pharmacist you visit that you are using Caspofungin AN.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how Caspofungin AN affects you.

Looking after your medicine

Caspofungin AN will be stored appropriately in the pharmacy or ward of a clinic or hospital.

It is kept in a refrigerator where the temperature stays between 2-8°C.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
  • Vein irritations where you had the injection, including redness, swelling or clotting
  • Headache, dizziness, pain, chills
  • Nausea, vomiting
  • Diarrhoea, stomach pain
  • Flushing, tremor, sweating
  • High blood pressure
  • Aching muscles, joints or bones
  • Difficulty sleeping
  • Swelling of the hands, ankles or feet.
Speak to your doctor if you have any of these less serious side effects and they worry you.

These are the more common side effects of Caspofungin AN. For the most part these have been mild

Serious side effects

Serious side effectsWhat to do
  • Fever that has developed or worsened after starting treatment with Caspofungin AN
  • Signs of anaemia such as tiredness, being short of breath, looking pale
  • Skin rash or itching
  • Pinkish, itchy swellings on the skin, also called hives or nettle rash
  • Difficulty breathing, shortness of breath or faster rate of breathing than usual
  • Swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing
  • Fast heart rate
  • Numbness or tingling in fingers or toes
  • Skin peeling, mucous membrane sores, large areas of peeling skin.
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What Caspofungin AN contains

Active ingredient
(main ingredient)		Caspofungin acetate
Other ingredients
(inactive ingredients)
  • Sucrose
  • Mannitol
  • Sodium hydroxide
  • Hydrochloric acid

Do not take this medicine if you are allergic to any of these ingredients.

What Caspofungin AN looks like

Caspofungin AN comes as a white to off-white powder in a glass vial.

Caspofungin AN is supplied as:

CASPOFUNGIN AN Caspofungin (as acetate) 50 mg powder for injection vial (AUST R 269932)

CASPOFUNGIN AN Caspofungin (as acetate) 70 mg powder for injection vial (AUST R 276642)

Who distributes Caspofungin AN

Juno Pharmaceuticals Pty Ltd
15 – 17 Chapel Street,
Cremorne,
VIC 3121
Australia

This leaflet was prepared in June 2025

Published by MIMS July 2025

BRAND INFORMATION

Brand name

Caspofungin AN

Active ingredient

Caspofungin

Schedule

S4

 

1 Name of Medicine

Caspofungin (as acetate).

2 Qualitative and Quantitative Composition

Caspofungin AN is a sterile, lyophilised product for intravenous infusion that contains a semisynthetic lipopeptide (echinocandin) compound synthesised from a fermentation product of Glarea lozoyensis. Caspofungin AN is the first of a new class of antifungal drugs (echinocandins) that inhibit the synthesis of β (1,3)-D-glucan, an integral component of the fungal cell wall.
Caspofungin AN contains 50 mg or 70 mg of caspofungin acetate as the active ingredient. Caspofungin acetate is a hygroscopic, white to off-white powder. It is freely soluble in water and methanol, and slightly soluble in ethanol. The pH of a saturated aqueous solution of caspofungin acetate is approximately 6.6.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Caspofungin AN is available as a white to off white lyophilised compact powder for infusion in single use glass vials of 50 mg and 70 mg.

4 Clinical Particulars

4.1 Therapeutic Indications

Caspofungin AN is indicated for:
empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics;
treatment of:
invasive Candidiasis, including candidaemia; oesophageal Candidiasis; invasive Aspergillosis in patients who are refractory to or intolerant of other therapies.

4.2 Dose and Method of Administration

Dosage.

Caspofungin AN should be administered in adult patients by slow intravenous infusion over approximately 1 hour (see Reconstitution section for dilution recommendations). See Table 1.

General recommendations in adult patients.

Empirical therapy. Duration of treatment should be based on the patient's clinical response. Empirical therapy should be continued until resolution of neutropenia, which is generally expected to occur within 28 days. Patients found to have a fungal infection should be treated for a minimum of 14 days; treatment should continue for at least 7 days after both neutropenia and clinical symptoms are resolved. If the 50 mg dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg. Although an increase in efficacy with 70 mg daily has not been demonstrated, safety data suggest that an increase in dose to 70 mg daily is well tolerated.
Candidiasis.

Invasive.

Duration of treatment of invasive candidiasis should be dictated by the patient's clinical and microbiological response. In general, antifungal therapy should continue for at least 14 days after the last positive culture. Patients who remain persistently neutropenic may warrant a longer course of therapy pending resolution of the neutropenia.

Oesophageal.

Increasing doses of caspofungin above 50 mg daily provided no additional benefit in the treatment of oesophageal candidiasis.
Invasive aspergillosis. Duration of treatment should be based upon the severity of the patient's underlying disease, recovery from immunosuppression, and clinical response. The efficacy of a 70 mg dose regimen in patients who are not clinically responding to the 50 mg daily dose is not known.
Safety data suggest that an increase in dose to 70 mg daily is well tolerated. The efficacy of doses above 70 mg has not been adequately studied in patients with invasive aspergillosis.

Concomitant therapy with inducers of drug clearance.

When Caspofungin AN is co-administered in adult patients with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, rifampicin, dexamethasone or carbamazepine, use of a daily dose of 70 mg of caspofungin should be considered.

Hepatic insufficiency.

Adult patients with mild hepatic insufficiency (Child-Pugh score 5 to 6) do not need a dosage adjustment.
Adult patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), require an adjustment to maintenance dosage (see Table 1).
There is no clinical experience in adult patients with severe hepatic insufficiency (Child-Pugh score > 9) (see Section 5.2 Pharmacokinetic Properties, Special populations) and in paediatric patients with any degree of hepatic insufficiency.

Renal insufficiency.

No dosage adjustment is necessary for patients with renal insufficiency. Caspofungin is not dialysable, thus supplementary dosing is not required following haemodialysis (see Section 5.2 Pharmacokinetic Properties, Special populations).

Paediatric patients.

Caspofungin AN should be administered in paediatric patients (3 months to 17 years of age) by slow IV infusion over approximately 1 hour. Dosing in paediatric patients (3 months to 17 years of age) should be based on the patient's body surface area (see Instructions for use in paediatric patients, Mosteller1 formula).
For all indications, a single 70 mg/m2 loading dose (not to exceed an actual dose of 70 mg) should be administered on Day 1, followed by 50 mg/m2 daily thereafter (not to exceed an actual dose of 70 mg daily). Duration of treatment should be individualised to the indication, as described for each indication in adults (see General recommendations in adult patients).
If the 50 mg/m2 daily dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg/m2 daily (not to exceed an actual daily dose of 70 mg). Although an increase in efficacy with 70 mg/m2 daily has not been demonstrated, limited safety data suggest that an increase in dose to 70 mg/m2 daily is well tolerated.
The efficacy and safety of Caspofungin AN have not been sufficiently studied in clinical trials involving neonates and infants below 12 months of age. Caution is advised when treating this age group. Limited data suggest that Caspofungin AN at 25 mg/m2 daily in neonates and infants (less than 3 months of age) and 50 mg/m2 daily in young children (3 to 11 months of age) can be considered.
When Caspofungin AN is co-administered to paediatric patients with inducers of drug clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a Caspofungin AN dose of 70 mg/m2 daily (not to exceed an actual daily dose of 70 mg) may need to be considered depending on the clinical response.
1Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med 1987 Oct 22;317(17): 1098 (letter).

Reconstitution of Caspofungin AN.

The reconstituted vial of Caspofungin AN must be further diluted prior to administration. Do not use diluents containing glucose as Caspofungin AN is not stable in diluents containing glucose.
Caspofungin AN should be administered by slow IV infusion of approximately 1 hour. It contains no antimicrobial agent. Product is for single use in one patient only. Discard any residue.
Do not mix or co-infuse Caspofungin AN with other medications as there is no data available on the compatibility of Caspofungin AN with other intravenous substances, additives, or medications.

Instructions for use in adults.

Step 1: reconstitution of vials.

To reconstitute the powdered drug, bring the refrigerated vial of Caspofungin AN to room temperature and aseptically add 10.5 mL of 0.9% sodium chloride injection or water for injections. The concentrations of the reconstituted vials will be: 7.2 mg/mL (70 mg vial) or 5.2 mg/mL (50 mg vial).
The white to off-white compact powder will dissolve completely. Mix gently until a clear solution is obtained. Reconstituted solutions should be visually inspected for particulate matter or discolouration. This reconstituted solution is chemically and physically stable for up to 1 hour when held below 25°C. However, to reduce microbiological hazard, use as soon as practicable after dilution and if storage is necessary, hold at 2-8°C for not more than 1 hour.

Step 2: addition of reconstituted Caspofungin AN to infusion solution.

The patient infusion solution is prepared by aseptically adding the appropriate amount of reconstituted drug (as shown in Table 2) to a 250 mL intravenous PVC bag or glass bottle of 0.9% sodium chloride injection. Reduced volume infusions in 100 mL may be used, when medically necessary, for 50 mg or 35 mg daily doses.
Visually inspect the infusion solution for particulate matter or discolouration. Do not use if the solution is cloudy or precipitated. This infusion solution is chemically and physically stable for 24 hours when stored below 25°C. However, to reduce microbiological hazard, use as soon as practicable after dilution and if storage is necessary, hold at 2-8°C for not more than 24 hours. Caspofungin AN should be administered by slow intravenous infusion over approximately 1 hour. It contains no antimicrobial agent. Use once only and discard any residue.

Instructions for use in paediatric patients.

Calculation of body surface area (BSA) for paediatric dosing.

Before preparation of infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller formula).

Preparation of the 70 mg/m2 infusion for paediatric patients 3 months of age or older (using a 70 mg vial).

1. Determine the actual loading dose to be used in the paediatric patient by using the patient's BSA (as calculated above) and the following equation:
BSA (m2) X 70 mg / m2 = Loading Dose
The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient's calculated dose.
2. Equilibrate the refrigerated vial of Caspofungin AN to room temperature.
3. Aseptically add 10.5 mL of 0.9% sodium chloride injection or sterile water for injectiona. This reconstituted solution may be stored for up to one hour at ≤ 25°Cb. This will give a final caspofungin concentration in the vial of 7.2 mg/mL.
4. Remove the volume of drug equal to the calculated loading dose (Step 1) from the vial. Aseptically transfer this volume (mL) of reconstituted Caspofungin AN to an IV bag (or bottle) containing 250 mL of 0.9%, 0.45%, or 0.225% sodium chloride injection, or lactated Ringers injection. Alternatively, the volume (mL)c of reconstituted Caspofungin AN can be added to a reduced volume of 0.9%, 0.45%, or 0.225%.
Sodium chloride injection or lactated Ringers injection, not to exceed a final concentration of 0.5 mg/mL. This infusion solution must be used within 24 hours if stored at ≤ 25°C or within 24 hours if stored refrigerated at 2 to 8°C.
5. If the calculated loading dose is < 50 mg, then the dose may be prepared from the 50 mg vial [follow Steps 2-4 from Preparation of the 50 mg/m2 infusion for paediatric patients 3 months of age or older (using a 50 mg vial)]. The final caspofungin concentration in the 50 mg vial after reconstitution is 5.2 mg/mL.

Preparation of the 50 mg/m2 infusion for paediatric patients 3 months of age or older (using a 50 mg vial).

1. Determine the daily maintenance dose to be used in the paediatric patient by using the patient's BSA (as calculated above) and the following equation:
BSA (m2) X 50 mg/m2 = Daily Maintenance Dose (mg)
The daily maintenance dose should not exceed 70 mg regardless of the patient's calculated dose.
2. Equilibrate the refrigerated vial of Caspofungin AN to room temperature.
3. Aseptically add 10.5 mL of 0.9% sodium chloride injection or sterile water for injectiona. This reconstituted solution may be stored for up to one hour at ≤ 25°Cb. This will give a final caspofungin concentration in the vial of 5.2 mg/mL.
4. Remove the volume of drug equal to the calculated loading dose (Step 1) from the vial. Aseptically transfer this volume (mL)c of reconstituted Caspofungin AN to an IV bag (or bottle) containing 250 mL of 0.9%, 0.45%, or 0.225% sodium chloride injection, or lactated Ringers injection. Alternatively, the volume (mL)c of reconstituted Caspofungin AN can be added to a reduced volume of 0.9%, 0.45%, or 0.225% sodium chloride injection or lactated Ringers injection, not to exceed a final concentration of 0.5 mg/mL. This infusion solution must be used within 24 hours if stored at ≤ 25°C or within 24 hours if stored refrigerated at 2 to 8°C.
5. If the actual daily maintenance dose is > 50 mg, then the dose may be prepared from the 70 mg vial [follow steps 2-4 from Preparation of the 70 mg/m2 infusion for paediatric patients 3 months of age or older (using a 70 mg vial)]. The final caspofungin concentration in the 70 mg vial after reconstitution is 7.2 mg/L.

Preparation notes.

a. The white to off-white cake will dissolve completely. Mix gently until a clear solution is obtained.
b. Visually inspect the reconstituted solution for particulate matter or discolouration during reconstitution and prior to infusion. Do not use if the solution is cloudy or has precipitated.
c. Caspofungin AN is formulated to provide the full labelled vial dose (70 mg or 50 mg) when 10 mL is withdrawn from the vial.

4.3 Contraindications

Caspofungin AN is contraindicated in patients with hypersensitivity to any component of this product.

4.4 Special Warnings and Precautions for Use

General.

Anaphylaxis has been reported during administration of caspofungin. If this occurs, caspofungin should be discontinued and appropriate treatment administered. Possibly histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth, or bronchospasm have been reported and may require discontinuation and/or administration of appropriate treatment.
Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported after post marketing use of caspofungin. Caution should apply in patients with history of allergic skin reactions.
Safety information on treatment durations longer than 4 weeks is limited, however available data suggest that caspofungin continues to be well tolerated with longer courses of therapy.
Laboratory abnormalities in liver function tests have been seen in healthy volunteers and in adult and paediatric patients treated with caspofungin. In some adult and paediatric patients with serious underlying conditions who were receiving multiple concomitant medications with caspofungin, isolated cases of clinically significant hepatic dysfunction, hepatitis, and hepatic failure have been reported; a causal relationship to caspofungin has not been established. Patients who develop abnormal liver function tests during caspofungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing caspofungin therapy.

Use in the elderly.

No data available.

Paediatric use.

The use of caspofungin in paediatric patients 3 months to 17 years of age is supported by efficacy/safety studies in adults, pharmacokinetic studies in paediatric patients (see Section 5.2 Pharmacokinetic Properties) and two prospective efficacy studies in paediatric patients (see Section 5.1 Pharmacodynamic Properties, Clinical trials).
The efficacy and safety of caspofungin has not been studied in prospective clinical trials involving neonates and infants under 3 months of age.
Caspofungin has not been studied in paediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida. Caspofungin has also not been studied as initial therapy for invasive aspergillosis in paediatric patients.
The pharmacokinetic, efficacy, and safety data for patients aged 3 to 12 months of age are limited. Caution is advised when treating this age group.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

See Table 3.

Cyclosporin.

Concomitant use of caspofungin with cyclosporin has been evaluated in healthy adult volunteers and in adult patients. In one clinical study, 3 of 4 healthy adult subjects who received caspofungin 70 mg on Days 1 through 10, and also received two 3 mg/kg doses of cyclosporin 12 hours apart on Day 10, developed transient elevations of alanine transaminase (ALT) on Day 11 that were 2 to 3 times the upper limit of normal (ULN). In a separate panel of adult subjects in the same study, 2 of 8 who received caspofungin 35 mg daily for 3 days and cyclosporin (two 3 mg/kg doses administered 12 hours apart) on Day 1 had small increases in ALT (slightly above the ULN) on Day 2. In both groups, elevations in aspartate transaminase (AST) paralleled ALT elevations, but were of lesser magnitude (see Section 4.8 Adverse Effects (Undesirable Effects), Laboratory abnormalities).
In the above two clinical studies, cyclosporin increased the AUC of caspofungin by approximately 35%. These AUC increases are probably due to reduced uptake of caspofungin by the liver. Caspofungin did not increase the plasma levels of cyclosporin. See Table 3.
A retrospective study was conducted of 40 adult patients treated during marketed use with caspofungin and cyclosporin for 1 to 290 days (median 17.5 days). The majority of patients had allogeneic haematopoietic stem cell transplants (82.5%) or solid organ transplants (10%). The majority of patients received caspofungin 50 mg daily after 70 mg on Day 1. No serious hepatic adverse events were noted during this study. As expected in this population, hepatic enzyme abnormalities occurred commonly; however, no patient had elevations in ALT that were considered drug related. Elevations in AST considered at least possibly related to therapy with caspofungin and/or cyclosporin occurred in 5 patients, but all were less than 3.6 times the ULN. Discontinuations due to laboratory abnormalities in hepatic enzymes from any cause occurred in 4 patients. Of these, 2 were considered possibly related to therapy with caspofungin and/or cyclosporin as well as other possible causes. In the prospective invasive aspergillosis and compassionate use studies, there were 6 patients treated with caspofungin and cyclosporin for 2 to 56 days; none of these patients experienced increases in hepatic enzymes.
These data suggest that caspofungin can be used in patients receiving cyclosporin when the potential benefit outweighs the potential risk.

Tacrolimus.

Clinical studies in healthy adult volunteers show that the pharmacokinetics of caspofungin are not altered by tacrolimus. Caspofungin reduced the blood AUC of tacrolimus by approximately 20%, maximal blood concentration (Cmax) by 16%, and 12 hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of caspofungin 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended. See Table 3.

Effect of caspofungin on the P450 (CYP) system.

Studies in vitro show that caspofungin is not an inhibitor of cytochrome P450 (CYP) mediated reactions. In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs. Caspofungin is not a substrate for P-glycoprotein, and metabolism by cytochrome P450 was not observed in vitro.

Other drugs.

Clinical studies in healthy adult volunteers show that the pharmacokinetics of caspofungin are not altered by itraconazole, amphotericin B, nelfinavir or mycophenolate. Caspofungin has no effect on the pharmacokinetics of itraconazole, amphotericin B, rifampicin or the active metabolite of mycophenolate. See Table 3.
Population pharmacokinetic screening of caspofungin concentrations in adult patients receiving other concomitant medications indicate that elevations in plasma caspofungin levels due to drug interactions, as was seen in the formal drug interaction study with cyclosporin, are uncommon. Results from two clinical drug interaction studies indicate that rifampicin both induces and inhibits caspofungin disposition with net induction at steady state. In one study, rifampicin and caspofungin were co-administered for 14 days with both therapies initiated on the same day. In the second study, rifampicin was administered alone for 14 days to allow the induction effect to reach steady state, and then rifampicin and caspofungin were co-administered for an additional 14 days. When the induction effect of rifampicin was at steady state, there was little change in caspofungin AUC or end-of-infusion concentration, but caspofungin trough concentrations were reduced by approximately 30%.
The inhibitory effect of rifampicin was demonstrated when rifampicin and caspofungin treatments were initiated on the same day, and a transient elevation in caspofungin plasma concentrations occurred on Day 1 (approximately 60% increase in AUC). This inhibitory effect was not seen when caspofungin was added to pre-existing rifampicin therapy, and no elevation in caspofungin concentrations occurred. See Table 3. In addition, results from the population pharmacokinetic screening suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone or carbamazepine) with caspofungin may also result in clinically meaningful reductions in caspofungin concentrations. Available data suggest that the inducible drug clearance mechanism involved in caspofungin disposition is likely an uptake transport process, rather than metabolism.
When caspofungin is co-administered in adult patients with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, rifampicin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg caspofungin should be considered.
In paediatric patients, results from regression analyses of pharmacokinetic data suggest that co-administration of dexamethasone with caspofungin may result in clinically meaningful reductions in caspofungin trough concentrations. This finding may indicate that paediatric patients will have similar reductions with inducers as seen in adults. When caspofungin is co-administered to paediatric patients with inducers of drug clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a caspofungin dose of 70 mg/m2 daily (not to exceed an actual daily dose of 70 mg) may need to be considered depending on the clinical response.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Fertility and reproductive performance were not affected by the intravenous administration of caspofungin to rats at IV doses of up to 5 mg/kg/day. At 5 mg/kg/day, drug exposures (AUC) were similar to those seen in patients treated with the 70 mg dose.
(Category B3)
Caspofungin was shown to be weakly embryotoxic in rats and rabbits. In rats, caspofungin was shown to cause the complete ossification of the skull and torso and an increased incidence of cervical rib. Caspofungin also produced increases in resorptions in rats and rabbits and pre-implantation losses in rats. These findings were observed at doses that produced drug exposures similar to those seen in patients treated with a 70 mg dose (1-2 fold clinical exposure at the maximum recommended dose, based on AUC). Caspofungin crossed the placental barrier in rats and rabbits and was detected in the plasma of foetuses of pregnant animals dosed with caspofungin. There were no adequate and well-controlled studies in pregnant women. Caspofungin should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.
 Caspofungin was found in the milk of lactating, drug-treated rats. It is not known whether caspofungin is excreted in human milk. Because many drugs are excreted in human milk, women receiving caspofungin should not breast-feed.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of this registration.

4.8 Adverse Effects (Undesirable Effects)

General.

Hypersensitivity reactions have been reported (see Section 4.4 Special Warnings and Precautions for Use).

Clinical adverse experiences in adult patients.

The overall safety of caspofungin was assessed in 1865 adult individuals who received single or multiple doses of caspofungin acetate: 564 febrile, neutropenic patients (empirical therapy study), 382 patients with invasive candidiasis, 297 patients with oesophageal and/or oropharyngeal candidiasis, 228 patients with invasive aspergillosis and 394 individuals in phase I studies. In the empirical therapy study, patients had received chemotherapy for malignancy or had undergone haematopoietic stem-cell transplantation. In the studies involving patients with documented Candida infections, the majority of the patients had serious underlying medical conditions (e.g. haematologic or other malignancy, recent major surgery, HIV) requiring multiple concomitant medications. Patients in the non-comparative Aspergillus study often had serious predisposing medical conditions (e.g. bone marrow or peripheral stem cell transplants, haematologic malignancy, solid tumours or organ transplants) requiring multiple concomitant medications.

Empirical therapy in febrile, neutropenic patients.

In the randomised, double-blinded empirical therapy study, patients received either caspofungin 50 mg/day (following a 70 mg loading dose) or AmBisome (3 mg/kg/day). Drug-related clinical adverse experiences occurring in ≥ 2% of the patients in either treatment group are presented in Table 4.
The proportion of patients who experienced an infusion-related adverse event was significantly lower in the group treated with caspofungin 35.1%) than in the group treated with AmBisome (51.6%).
To evaluate the effect of caspofungin and AmBisome on renal function, nephrotoxicity was defined as doubling of serum creatinine relative to baseline or an increase of ≥ 1 mg/dL in serum creatinine if baseline serum creatinine was above the upper limit of the normal range. Among patients whose baseline creatinine clearance was > 30 mL/min, the incidence of nephrotoxicity was significantly lower in the group treated with caspofungin (2.6%) than in the group treated with AmBisome (11.5%).

Invasive candidiasis.

In an initial randomised, double-blinded invasive candidiasis study, patients received either caspofungin 50 mg/day (following a 70 mg loading dose) or amphotericin B, 0.6 to 1.0 mg/kg/day. Drug-related clinical adverse experiences occurring in ≥ 2% of the patients in either treatment group are presented in Table 5.
The incidence of drug-related clinical adverse experiences was significantly lower among patients treated with caspofungin (28.9%) than among patients treated with amphotericin B (58.4%). Also, the proportion of patients who experienced an infusion-related adverse event was significantly lower in the caspofungin group (20.2%) than in the amphotericin B group (48.8%).
In a second randomised, double-blinded invasive candidiasis study, patients received either caspofungin 50 mg/day (following a 70 mg loading dose) or caspofungin 150 mg/day. The primary endpoint for this study was the proportion of patients developing a significant drug-related adverse experience (defined as a serious drug-related adverse experience or a drug-related adverse experience leading to caspofungin discontinuation). The proportion of patients with a significant drug-related adverse experience was comparable in the 2 treatment groups: 1.9% (2/104) vs. 3.0% (3/100) in the caspofungin 50 mg/day and 150 mg/day groups, respectively (difference 1.1% [95% CI -4.1, 6.8]). The proportion of patients who experienced any drug-related adverse experience was also similar in the 2 treatment groups. Drug-related clinical adverse experiences occurring in ≥ 2.0% of the patients in either treatment group are presented in Table 6.

Oesophageal and/or oropharyngeal candidiasis.

Drug-related clinical adverse experiences occurring in ≥ 2% of patients with oesophageal and/or oropharyngeal candidiasis are presented in Table 7.

Invasive aspergillosis.

In the open-label, non-comparative aspergillosis study, in which 69 patients received caspofungin (70 mg loading dose on Day 1 followed by 50 mg daily), the following drug-related clinical adverse experiences were observed with an incidence of ≥ 2%: fever (2.9%), infused-vein complications (2.9%), nausea (2.9%), vomiting (2.9%) and flushing (2.9%). Also reported infrequently in this patient population were pulmonary oedema, adult respiratory distress syndrome (ARDS), and radiographic infiltrates.

Clinical adverse experiences in paediatric patients.

The overall safety of caspofungin was assessed in 171 paediatric patients who received single or multiple doses of caspofungin: 104 febrile, neutropenic patients; 56 patients with invasive candidiasis; 1 patient with oesophageal candidiasis; and 10 patients with invasive aspergillosis. The overall clinical safety profile of caspofungin in paediatric patients is comparable to that in adult patients. Table 8 shows the incidence of drug-related clinical adverse experiences reported in ≥ 2.0% of paediatric patients in clinical studies. The most common drug-related clinical adverse experiences in paediatric patients treated with caspofungin were fever (11.7%), rash (4.7%), and headache (2.9%).
One patient (0.6%) receiving caspofungin and three patients (11.5%) receiving AmBisome developed a serious drug-related clinical adverse experience. Two patients (1.2%) were discontinued from caspofungin and three patients (11.5%) were discontinued from AmBisome due to a drug-related clinical adverse experience. The proportion of patients who experienced an infusion-related adverse event was 21.6% in the group treated with caspofungin and 34.6% in the group treated with AmBisome.

Laboratory values.

Adult patients.

Empirical therapy in febrile, neutropenic patients.

Drug-related laboratory adverse experiences occurring in ≥ 2% of the patients in either treatment group are presented in Table 9.
The percentage of patients with either a drug-related clinical or a drug-related laboratory adverse experience was significantly lower among patients receiving caspofungin (54.4%) than among patients receiving AmBisome (69.3%). Furthermore, the incidence of discontinuation due to a drug-related clinical or laboratory adverse experience was significantly lower among patients treated with caspofungin (5.0%) than among patients treated with AmBisome (8.0%).

Invasive candidiasis.

Drug-related laboratory adverse experiences occurring in ≥ 2% of the patients in an initial invasive candidiasis study are presented in Table 10.
The incidence of drug-related laboratory adverse experiences was significantly lower among patients receiving caspofungin (24.3%) than among patients receiving amphotericin B (54.0%).
The percentage of patients with either a drug-related clinical adverse experience or a drug-related laboratory adverse experience was significantly lower among patients receiving caspofungin (42.1%) than among patients receiving amphotericin B (75.2%). Furthermore, a significant difference between the two treatment groups was observed with regard to incidence of discontinuation due to drug-related clinical or laboratory adverse experience; 3/114 (2.6%) in the caspofungin group and 29/125 (23.2%) in the amphotericin B group.
To evaluate the effect of caspofungin and amphotericin B on renal function, nephrotoxicity was defined as doubling of serum creatinine relative to baseline or an increase of ≥ 1 mg/dL in serum creatinine if baseline serum creatinine was above the upper limit of the normal range. In a subgroup of patients whose baseline creatinine clearance was > 30 mL/min, the incidence of nephrotoxicity was significantly lower in the caspofungin group than in the amphotericin B group.
In a second randomised, double-blinded invasive candidiasis study, patients received either caspofungin 50 mg/day (following a 70 mg loading dose) or caspofungin 150 mg/day. Drug-related laboratory adverse experiences occurring in ≥ 2.0% of the patients in either treatment group are presented in Table 11.

Oesophageal and/or oropharyngeal candidiasis.

Drug-related laboratory abnormalities occurring in ≥ 2% of patients with oesophageal and/or oropharyngeal candidiasis are presented in Table 12.

Invasive aspergillosis.

Drug-related laboratory abnormalities reported with an incidence ≥ 2% in patients treated with caspofungin in the non-comparative aspergillosis study were: serum alkaline phosphatase increased (2.9%), serum potassium decreased (2.9%), eosinophils increased (3.2%), urine protein increased (4.9%), and urine RBCs increased (2.2%).
The safety and efficacy of multiple doses up to 150 mg daily (range: 1 to 51 days; median: 14 days) have been studied in 100 adult patients with invasive candidiasis. Caspofungin was generally well tolerated in these patients receiving caspofungin at this higher dose; however, the efficacy of caspofungin at this higher dose was generally similar to patients receiving the 50 mg daily dose of caspofungin.
Paediatric patients. Table 13 shows the incidence of drug-related laboratory adverse experiences reported in ≥ 2.0% of paediatric patients in clinical studies. The overall laboratory safety profile in paediatric patients is comparable to that in adult patients. The most common drug-related laboratory adverse experiences in paediatric patients treated with caspofungin were increased ALT (6.5%) and increased AST (7.6%). None of the patients receiving caspofungin or AmBisome developed a serious drug-related adverse event or were discontinued from therapy due to a drug-related laboratory adverse experience.

Post-marketing experience.

The following post-marketing adverse events have been reported:

Hepatobiliary.

Rare cases of hepatic dysfunction.

Skin and subcutaneous tissue disorders.

Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Cardiovascular.

Swelling and peripheral oedema.

Metabolic.

Hypercalcaemia; gamma-glutamyltransferase increased.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems.

4.9 Overdose

In clinical studies the highest dose was 210 mg, which was administered as a single dose to 6 healthy subjects and was generally well tolerated. In addition, 150 mg daily up to 51 days has been administered to 100 healthy patients and was generally well-tolerated. Caspofungin is not dialysable.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Caspofungin (as acetate), the active ingredient of Caspofungin AN, inhibits the synthesis of β (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi and yeast. β (1,3)-D-glucan is not present in mammalian cells.

Microbiology.

Activity in vitro.

Caspofungin has in vitro activity against:
Aspergillus species (including Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, Aspergillus terreus and Aspergillus candidus).
Candida species (including Candida albicans, Candida dubliniensis, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lipolytica, Candida lusitaniae, Candida parapsilosis, Candida rugosa, and Candida tropicalis).
Susceptibility testing was performed according to a modification of both the Clinical and Laboratory Standards Institute (CLSI, formerly known as the National Committee for Clinical Laboratory Standards (NCCLS) method M38-A2 (for Aspergillus species) and method M27- A3 (for Candida species).
Interpretive standards (or breakpoints) for caspofungin against Candida species are applicable only to tests performed using CLSI microbroth dilution reference method M27-A3 for minimum inhibitory concentrations (MIC) read as a partial inhibition endpoint at 24 hours. The MIC values for caspofungin using CLSI microbroth dilution reference method M27-A3 should be interpreted according to the criteria provided in Table 14 (CLSI M27-S3).
There are no established breakpoints for caspofungin against Candida species using the European Committee for Antimicrobial Susceptibility Testing (EUCAST) method.
Standardised techniques for susceptibility testing have been established for yeasts by EUCAST. No standardised techniques for susceptibility testing or interpretive breakpoints have been established for Aspergillus species and other filamentous fungi using either the CLSI or EUCAST method.

Activity in vivo.

Caspofungin was active when parenterally administered to immune-competent and immune-suppressed animals with disseminated infections of Aspergillus and Candida for which the endpoints were prolonged survival of infected animals (Aspergillus and Candida) and clearance of fungi from target organs (Candida). Caspofungin was also active in immunodeficient animals after disseminated infection with C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, or C. tropicalis in which the endpoint was clearance of Candida from target organs. Caspofungin has been reported to be active in the prevention and treatment of pulmonary aspergillosis in a rat model.

Cross-resistance.

Caspofungin acetate is active against strains of Candida with intrinsic or acquired resistance to fluconazole, amphotericin B, or flucytosine consistent with their different mechanisms of action.

Drug resistance.

A caspofungin MIC of ≤ 2 microgram/mL ("Susceptible" per Table 14) using the CLSI M27-A3 method indicates that the Candida isolate is likely to be inhibited if caspofungin therapeutic concentrations are achieved. Breakthrough infections with Candida isolates requiring caspofungin concentrations > 2 microgram/mL for growth inhibition have developed in a mouse model of C. albicans infection. Isolates of Candida with reduced susceptibility to caspofungin have been identified in a small number of patients during treatment (MICs for caspofungin > 2 microgram/mL using standardised MIC testing techniques approved by the CLSI). Some of these isolates had mutations in the FKS1/FKS2 gene. Although the incidence is rare, these cases have been routinely associated with poor clinical outcomes.
Development of in vitro resistance to caspofungin by Aspergillus species has been identified. In clinical experience, drug resistance in patients with invasive aspergillosis has been observed. The mechanism of resistance has not been established.
The incidence of drug resistance in various clinical isolates of Candida and Aspergillus species is rare.

Clinical trials.

The results of the adult clinical studies are presented by each indication below, followed thereafter by the results of paediatric clinical trials.

Empirical therapy in febrile, neutropenic patients.

A multicentre, double-blind study enrolled 1111 febrile, neutropenic, adult patients (mean age 48 years, range 16-83; 56% male) who were randomised to treatment with daily doses of caspofungin (50 mg/day following a 70 mg loading dose on Day 1) or AmBisome2 (liposomal amphotericin for injection, 3.0 mg/kg/day). Eligible patients had received chemotherapy for malignancy or had undergone haematopoietic stem-cell transplantation (HSCT), and presented with neutropenia (< 500 cells/mm3 for 96 hours) and fever (> 38.0°C) that had not responded to antibacterial therapy. Any patient known to have a documented fungal infection was excluded from entering the study. Patients were to be treated until resolution of neutropenia, with a maximum treatment duration of 28 days. However, patients found to have a documented fungal infection could be treated longer. If the drug was well tolerated but the patient's fever persisted and clinical condition deteriorated following 5 days of therapy, the dosage of study drug could be increased to 70 mg/day for caspofungin (13.3% of patients treated) or to 5.0 mg/kg/day for AmBisome (14.3% of patients treated).
Patients were stratified based on risk category [high-risk patients had undergone allogeneic HSCT (7.0% total) or had relapsed acute leukaemia (17.7% total)] and on receipt of prior antifungal prophylaxis. The percentage of patients in the high-risk stratum at entry was 26.6% for the caspofungin group and 22.9% for the AmBisome group. In both groups a similar percentage of patients had received antifungal prophylaxis. The most frequent diagnoses were acute myelogenous leukaemia, acute lymphocytic leukaemia, and non-Hodgkin's lymphoma.
Patients who met the entry criteria and received at least one dose of study therapy were included in the modified intention-to-treat (MITT) population (556 treated with caspofungin and 539 treated with AmBisome). The mean duration of study therapy was 13 days. An overall favourable response required meeting each of 5 criteria: 1) successful treatment of any baseline fungal infection, 2) no breakthrough fungal infections during administration of study drug or within 7 days after completion of treatment, 3) survival for 7 days after completion of study therapy, 4) no discontinuation of the study drug because of drug-related toxicity or lack of efficacy, and 5) resolution of fever during the period of neutropenia.
An independent expert panel adjudicated blinded data from all patients identified as having a suspected invasive fungal infection. The panel assessed the presence of invasive fungal infection, timing of onset (baseline or breakthrough), causative pathogen, and, for baseline infections, response to study treatment. The only fungal infections considered to be present for purposes of statistical analysis were those classified by the expert panel as either probable or proven. Approximately 5% of patients were found to have baseline fungal infections, of which the majority were due to Aspergillus or Candida species.
The proportion of MITT patients with an overall favourable response and the proportion of MITT patients with favourable responses to the individual criteria are shown in Table 15.
2Registered trademark of Gilead Sciences, Inc.
Based on overall favourable response rates, caspofungin was as effective as AmBisome in empirical therapy of persistent febrile neutropenia. Caspofungin had significantly higher favourable response rates than AmBisome for the following criteria: successful treatment of any baseline fungal infection (caspofungin 51.9%, AmBisome 25.9%) and absence of premature discontinuation from study therapy due to toxicity or lack of efficacy (caspofungin 89.7%, AmBisome 85.5%). Caspofungin was comparable to AmBisome for the other criteria (absence of a breakthrough fungal infection, survival for 7 days after the end of treatment, and resolution of fever during neutropenia).
Overall favourable response rates were comparable in high-risk patients (caspofungin 43.2%, AmBisome 37.7%) and low-risk patients (caspofungin 31.0%, AmBisome 32.4%). Rates were also comparable in patients who had received prior antifungal prophylaxis (caspofungin 33.5%, AmBisome 32.9%) and those who had not (caspofungin 35.0%, AmBisome 34.5%).
The majority of baseline infections were due to Aspergillus or Candida species. Response rates to caspofungin and AmBisome for baseline infections caused by Aspergillus species were, respectively, 41.7% (5/12) and 8.3% (1/12), and by Candida species were 66.7% (8/12) and 41.7% (5/12).

Invasive candidiasis.

In an initial Phase III randomised, double-blind study, patients with a proven diagnosis of invasive candidiasis received daily doses of caspofungin (50 mg/day following a 70 mg loading dose on Day 1) or amphotericin B deoxycholate (0.6 to 0.7 mg/kg/day for non-neutropenic patients and 0.7 to 1.0 mg/kg/day for neutropenic patients). Patients were stratified by both neutropenic status and APACHE II score. Patients who met the entry criteria and received one or more doses of IV study therapy were included in the primary (modified intention-to-treat [MITT]) analysis of response at the end of IV study therapy. A predefined analysis to support the MITT, the evaluable-patients assessment, included patients who met entry criteria, received IV study therapy for 5 or more days and had a full efficacy evaluation at the end of IV study therapy. A favourable response required both symptom resolution and microbiological clearance of the Candida infection.
Of the 239 patients enrolled, 224 (109 treated with caspofungin and 115 treated with amphotericin B) met the criteria for inclusion in the MITT analysis. Of these patients, 185 (88 treated with caspofungin and 97 treated with amphotericin B) met the criteria for inclusion in the evaluable-patients analysis. The most frequent diagnoses were bloodstream infections (candidaemia) (83%) and Candida peritonitis (10%), patients with Candida endocarditis, osteomyelitis or meningitis were excluded from this study. Most infections were caused by C. albicans (45%), followed by C. parapsilosis (19%), C. tropicalis (16%), C. glabrata (11%), and C. krusei (2%). The favourable response rates at the end of IV study therapy are shown in Table 16.
Response rates were also consistent across all identified Candida species. For all other efficacy time points (Day 10 of IV study therapy, end of all antifungal therapy, 2-week post-therapy follow-up, and 6- to 8-week post-therapy follow-up), caspofungin was as effective as amphotericin B. Caspofungin was also comparable to amphotericin B with regard to relapse or survival rates, with an overall mortality among MITT patients during the study treatment period and 6 to 8-week follow-up period of 33.0% in the caspofungin group and 30.4% in the amphotericin B group.
Caspofungin was comparable to amphotericin B in the treatment of invasive candidiasis at the end of IV study therapy in the primary (MITT) efficacy analysis. In a predefined efficacy analysis of evaluable patients to support the MITT, caspofungin was statistically superior to amphotericin B at the end of IV study therapy.
Of the 224 patients from the invasive candidiasis study who met the criteria for inclusion in the MITT analysis, 186 patients (92 treated with caspofungin and 94 treated with amphotericin B) had candidaemia. Of these patients, 150 (71 treated with caspofungin and 79 treated with amphotericin B) met the criteria for inclusion in the evaluable-patients analysis. The favourable response rates at the end of IV study therapy for patients with candidaemia are shown in Table 16.
In both the MITT and evaluable-patients efficacy analyses, caspofungin was comparable to amphotericin B in the treatment of candidaemia at the end of IV study therapy.
In a second Phase III randomised, double-blind study, patients with a proven diagnosis of invasive candidiasis received daily doses of caspofungin 50 mg/day (following a 70 mg loading dose on Day 1) or caspofungin 150 mg/day. The diagnostic criteria, efficacy time points, and efficacy endpoints used in this study were similar to those employed in the prior study. Efficacy was a secondary endpoint in this study. Patients who met the entry criteria and received one or more doses of caspofungin study therapy were included in the efficacy analysis. The favorable overall response rates at the end of caspofungin therapy were similar in the 2 treatment groups: 72% (73/102) and 78% (74/95) for the caspofungin 50 mg and 150 mg treatment groups, respectively (difference 6.3% [95% CI -5.9, 18.4]).

Oesophageal candidiasis.

A total of 393 patients with oesophageal candidiasis were enrolled in three comparative studies to evaluate the efficacy of caspofungin for the treatment of oesophageal candidiasis. Patients were required to have symptoms and microbiological documentation of oesophageal candidiasis; and most patients were significantly immunocompromised. Disease severity was determined by oesophagoscopy (endoscopy).
In the randomised, double-blind study comparing caspofungin 50 mg/day (n=83) versus IV fluconazole 200 mg/day (n=94) for the treatment of oesophageal candidiasis, patients were treated for 7 to 21 days. A favourable overall response required both complete resolution of symptoms and significant endoscopic improvement 5 to 7 days following discontinuation of study therapy. The definition of endoscopic response was based on severity of disease at baseline using a 4 grade scale and required at least a two grade reduction from baseline endoscopic score or reduction to grade 0 for patients with a baseline score of 2 or less. The proportion of patients with a favourable response to caspofungin was comparable to that seen with fluconazole, as demonstrated in Table 17.
In addition, two double-blind, comparative dose-ranging studies evaluated 3 different doses of caspofungin (35, 50, 70 mg/day) and amphotericin B (0.5 mg/kg/day). These clinical studies support the use of caspofungin 50 mg daily in the treatment of oesophageal candidiasis. Increasing doses of caspofungin above 50 mg daily provided no additional benefit in the treatment of oesophageal candidiasis.

Invasive aspergillosis.

Sixty nine patients between the ages of 18 and 80 with invasive aspergillosis were enrolled in an open-label, non-comparative study to evaluate the safety, tolerability, and efficacy of caspofungin. Enrolled patients had previously been refractory to or intolerant of other antifungal therapy. Refractory patients were classified as those who had disease progression or failed to improve despite therapy for at least 7 days with amphotericin B, lipid formulations of amphotericin B, itraconazole, or an investigational azole (voriconazole) with reported activity against Aspergillus. Intolerance to previous therapy was defined as a doubling of creatinine (or creatinine ≥ 2.5 mg/dL while on therapy), other acute reactions, or infusion-related toxicity.
To be included in the study, patients with pulmonary disease must have had definite (positive tissue histopathology or positive culture from tissue obtained by an invasive procedure) or probable (positive radiographic or computed tomographic evidence with supporting culture from bronchoalveolar lavage or sputum, galactomannan enzyme-linked immunosorbent assay, and/or polymerase chain reaction) invasive aspergillosis.
Patients with extrapulmonary disease had to have definite invasive aspergillosis. The definitions were modelled after the Mycoses Study Group Criteria. Patients were administered a single 70 mg loading dose of caspofungin and subsequently dosed with 50 mg daily. The mean duration of therapy was 33.7 days, with a range of 1 to 162 days.
An independent expert panel evaluated patient data, including diagnosis of invasive aspergillosis, response and tolerability to previous antifungal therapy, treatment course on caspofungin, and clinical outcome.
A favourable response was defined as either complete resolution (complete response) or clinically meaningful improvement (partial response) of all signs and symptoms and attributable radiographic findings. Stable, nonprogressive disease was considered to be an unfavourable response.
Among the 69 patients enrolled in the study, 63 met entry diagnostic criteria and had outcome data; and of these, 52 patients received treatment for > 7 days. Fifty-three (84%) were refractory to previous antifungal therapy and 10 (16%) were intolerant. Forty five patients had pulmonary disease and 18 had extrapulmonary disease. Underlying conditions were haematologic malignancy (N=24), allogeneic bone marrow transplant or stem cell transplant (N=18), organ transplant (N=8), solid tumour (N=3), or other conditions (N=10). Fourteen patients were neutropenic (ANC < 500/microL) at baseline; two of these patients had a favourable response to caspofungin therapy and evidence of their clinical response was seen prior to recovery of their neutrophil counts. In addition, 3 patients who had become neutropenic during caspofungin therapy all had a favourable response. None of the 7 patients who were persistently neutropenic had a favourable response.
All patients in the study received concomitant therapies for their other underlying conditions. Eighteen patients received tacrolimus and caspofungin concomitantly, (of whom 8 also received mycophenolate mofetil); 5 of these 18 patients had a favourable response. Among the 23 patients receiving high-dose corticosteroids, 8 had a favourable response, including 5 who continued on high-dose steroids. Overall, the expert panel determined that 41% (26/63) of patients receiving at least one dose of caspofungin had a favourable response. For those patients who received > 7 days of therapy with caspofungin, 50% (26/52) had a favourable response. The favourable response rates for patients who were either refractory to or intolerant of previous therapies were 36% (19/53) and 70% (7/10), respectively. The response rates among patients with pulmonary disease and extrapulmonary disease were 47% (21/45) and 28% (5/18), respectively. Among patients with extrapulmonary disease, 2 of 8 patients who also had definite, probable, or possible CNS involvement had a favourable response.
A medical chart review of 206 patients with invasive aspergillosis was also conducted to assess the response to standard (non-investigational) therapies. Patient characteristics and important risk factors in this review were similar to those of patients enrolled in the open-label non-comparative study (see above), and the same rigorous definitions of diagnosis and outcome were used. To be included in this study, patients had to have had invasive aspergillosis and to have received at least 7 days of standard antifungal therapy. The favourable response rate from this historical control study was 17% (35/206) for standard therapy compared to the favourable response rate of 41% (26/63) for caspofungin in the open-label non-comparative study (the odds ratio was approximately 3).

Paediatric patients.

The safety and efficacy of caspofungin was evaluated in paediatric patients 3 months to 17 years of age in two prospective, multicentre clinical trials.
The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomised, double-blind study comparing caspofungin (50 mg/m2 IV once daily following a 70 mg/m2 loading dose on Day 1 [not to exceed 70 mg daily]) to AmBisome (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on AmBisome) as empirical therapy in paediatric patients with persistent fever and neutropenia. The study design and criteria for efficacy assessment were similar to the study in adult patients (see Clinical trials, Empirical therapy in febrile, neutropenic patients). Patients were stratified based on risk category (high-risk patients had undergone allogeneic stem cell transplantation or had relapsed acute leukaemia). Twenty-seven percent of patients in both treatment groups were high risk. The overall success rates in the MITT analysis, adjusted for strata, were as follows: 46% (26/56) for caspofungin and 32% (8/25) for AmBisome. For those patients in the high risk category, the favourable overall response rate was 60% (9/15) in the caspofungin group and 0% (0/7) in the AmBisome group.
The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in paediatric patients (ages 3 months to 17 years) with invasive candidiasis, oesophageal candidiasis, and invasive aspergillosis (as salvage therapy). The study employed diagnostic criteria which were based on established EORTC/MSG criteria of proven or probable infection; these criteria were similar to those criteria employed in the adult studies for these various indications. Similarly, the efficacy time points and endpoints used in this study were similar to those employed in the corresponding adult studies (see Clinical trials, Invasive candidiasis, candidaemia, Oesophageal candidiasis, Invasive aspergillosis). All patients received caspofungin at 50 mg/m2 IV once daily following a 70 mg/m2 loading dose on Day 1 (not to exceed 70 mg daily). Among the 49 enrolled patients who received caspofungin, 48 were included in the MITT analysis. Of these 48 patients, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had oesophageal candidiasis. The favourable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT analysis: 81% (30/37) in invasive candidiasis, 50% (5/10) in invasive aspergillosis, and 100% (1/1) in oesophageal candidiasis.

5.2 Pharmacokinetic Properties

Absorption.

Absorption is not relevant since caspofungin acetate is administered intravenously.

Distribution.

Plasma concentrations of caspofungin decline in a polyphasic manner following single 1-hour IV infusions. A short α-phase occurs immediately post-infusion, followed by a β-phase (half-life of 9 to 11 hours) that characterises much of the profile and exhibits clear log-linear behaviour from 6 to 48 hours post-dose (during which the plasma concentration decreases by an order of magnitude). An additional, longer half-life (γ-) phase, also occurs with a half-life of 40-50 hours.
Distribution, rather than excretion or biotransformation, is the dominant mechanism influencing plasma clearance. Caspofungin is extensively bound to albumin (~97%), and distribution into red blood cells is minimal. Mass balance results showed that approximately 92% of the [3H] label was found in tissues 36 to 48 hours after a single 70 mg dose of [3H] caspofungin acetate. There is little excretion or biotransformation of caspofungin during the first 30 hours after administration.

Metabolism.

Caspofungin is slowly metabolised by hydrolysis and N-acetylation. Caspofungin also undergoes spontaneous chemical degradation to an open-ring peptide compound, L-747969. At later time points (≥ 5 days post-dose), there is a low level (≤ 7 picomoles/mg protein, or ≤ 1.3% of administered dose) of covalent binding of radiolabel in plasma, following single-dose administration of [3H] caspofungin acetate. This may be due to two reactive intermediates formed during the chemical degradation of caspofungin to L-747969. Additional metabolism involves hydrolysis into constitutive amino acids and their degradates, including dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine. These two tyrosine derivatives are found only in urine, suggesting rapid clearance of these derivatives by the kidneys.

Excretion.

Two single-dose radiolabelled pharmacokinetic studies were conducted. In one study, plasma, urine, and faeces were collected over 27 days, and in the second study, plasma was collected over six months. Approximately 75% of the radioactivity was recovered: 41% in urine and 34% in faeces. Plasma concentrations of radioactivity and of caspofungin were similar during the first 24 to 48 hours post-dose; thereafter drug levels fell more rapidly. In plasma, caspofungin concentrations fell below the limit of quantitation after 6 to 8 days post-dose, while radio-label fell below the limit of quantitation at 22.3 weeks post-dose. A small amount of caspofungin is excreted unchanged in urine (~1.4% of dose). Renal clearance of parent drug is low (~0.15 mL/min).

Special populations.

Gender.

The plasma concentration of caspofungin was similar in healthy men and women on Day 1 following a single 70 mg dose. After 13 daily 50 mg doses, the area under the curve (AUC) for caspofungin was elevated slightly (approximately 20%) in women relative to men. No dosage adjustment is necessary based on gender.

Geriatric.

Plasma concentrations of caspofungin in healthy older men and women (≥ 65 years of age) were increased slightly (approximately 28% in area under the curve [AUC]) compared to young healthy men. In patients who were treated empirically or who had invasive candidiasis, a similar modest effect of age was seen in older patients relative to younger patients. No dosage adjustment is necessary for the elderly.

Race.

No clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, Hispanics, and persons of mixed race. No dosage adjustment is necessary on the basis of race.

Renal insufficiency.

In a clinical study of single 70 mg doses, caspofungin pharmacokinetics were similar in volunteers with mild renal insufficiency (creatinine clearance 50 to 80 mL/min) and control subjects. Moderate (creatinine clearance 31 to 49 mL/min), advanced (creatinine clearance 5 to 30 mL/min), and end-stage (creatinine clearance < 10 mL/min and dialysis dependent) renal insufficiency moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49% for AUC). However, in patients with invasive aspergillosis who received multiple daily doses of caspofungin 50 mg, there was no significant effect of mild to advanced renal impairment on caspofungin trough concentrations. No dosage adjustment is necessary for patients with renal insufficiency. Caspofungin is not dialysable, thus supplementary dosing is not required following haemodialysis.

Hepatic insufficiency.

Plasma concentrations of caspofungin after a single 70 mg dose in patients with mild hepatic insufficiency (Child-Pugh score 5 to 6) were increased by approximately 55% in AUC compared to healthy control subjects. In a 14-day multiple-dose study (70 mg on Day 1 followed by 50 mg daily thereafter), plasma concentrations in patients with mild hepatic insufficiency were increased modestly (21 to 26% in AUC) on Days 7 and 14 relative to healthy control subjects. No dosage adjustment is recommended for patients with mild hepatic insufficiency. Patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9) who received a single 70 mg dose of caspofungin had an average plasma caspofungin increase of 76% compared to control subjects.
A dosage reduction is recommended for patients with moderate hepatic insufficiency (see Section 4.2 Dose and Method of Administration). There is no clinical experience in patients with severe hepatic insufficiency (Child-Pugh score > 9).

Paediatric patients.

Caspofungin has been studied in five prospective studies involving paediatric patients under 18 years of age, including three paediatric pharmacokinetic studies (initial study in adolescents [12-17 years of age] and children [2-11 years of age] followed by a study in younger patients [3-23 months of age] and then followed by a study in neonates and infants [< 3 months]).
In adolescents (ages 12 to 17 years) receiving caspofungin at 50 mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr was generally comparable to that seen in adults receiving caspofungin at 50 mg daily. All adolescents received doses > 50 mg daily, and, in fact, 6 of 8 received the maximum dose of 70 mg/day. The caspofungin plasma concentrations in these adolescents were reduced relative to adults receiving 70 mg daily, the dose most often administered to adolescents.
In children (ages 2 to 11 years) receiving caspofungin at 50 mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg/day. On the first day of administration, AUC0-24 hr was somewhat higher in children than adults for these comparisons (37% increase for the 50 mg/m2/day to 50 mg/day comparison).
In young children and toddlers (ages 3 to 23 months) receiving caspofungin at 50 mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg daily. As in the older children, these young children who received 50 mg/m2 daily had slightly higher AUC0-24 hr values on Day 1 relative to adults receiving the standard 50-mg daily dose. The caspofungin pharmacokinetic results from the young children (3 to 23 months of age) that received 50 mg/m2 caspofungin daily were similar to the pharmacokinetic results from older children (2 to 11 years of age) that received the same dosing regimen.
In neonates and infants (< 3 months) receiving caspofungin at 25 mg/m2 daily, caspofungin peak concentration (C1 hr) and caspofungin trough concentration (C24 hr) after multiple doses were comparable to that seen in adults receiving caspofungin at 50 mg daily. On Day 1, C1 hr was comparable and C24 hr modestly elevated (36%) in these neonates and infants relative to adults. AUC0-24 hr measurements were not performed in this study due to the sparse plasma sampling. Of note, the efficacy and safety of caspofungin has not been adequately studied in prospective clinical trials involving neonates and infants under 3 months of age.
Based on population pharmacokinetic analyses including data from the 2 efficacy studies in paediatric population and in comparison with healthy adults and adult patients, the caspofungin C1 hr was significantly increased (50 - 163%) in paediatric patients of all age groups, whereas C24 hr was significantly increased (25 - 109%) in older children (2 - 11 years) and adolescents (12 - 17 years), but was similar to adults in young children (3 - 24 months).
The estimated increase in AUC0-24 hr was 38 - 41% in paediatric patients of all age groups compared with adult patients.
Overall, the available pharmacokinetic, efficacy, and safety data are limited in patients 3 to 10 months of age. Pharmacokinetic data from one 10-month old child receiving the 50 mg/m2 daily dose indicated an AUC0-24 hr within the same range as that observed in older children and adults at the 50 mg/m2 and the 50 mg dose, respectively, while in one 6-month old child receiving the 50 mg/m2 dose, the AUC0-24 hr was somewhat higher.

5.3 Preclinical Safety Data

Genotoxicity.

Caspofungin did not show evidence of genotoxic potential when evaluated in assays for gene mutation [bacterial (Ames) and mammalian cell (V79 Chinese hamster lung fibroblasts) assays] and chromosomal damage (Chinese hamster ovary cells in vitro and the mouse bone marrow chromosomal assay). Caspofungin was also negative in the alkaline elution/rat hepatocytes DNA strand break test.

Carcinogenicity.

No long-term studies in animals have been performed to evaluate the carcinogenic potential of caspofungin.

6 Pharmaceutical Particulars

6.1 List of Excipients

Sucrose, mannitol, hydrochloric acid, sodium hydroxide.

6.2 Incompatibilities

Do not mix or co-infuse Caspofungin AN with other medications as there is no data available on the compatibility of Caspofungin AN with other intravenous substances, additives, or medications.

6.3 Shelf Life

Reconstituted vials of Caspofungin AN may be stored for one hour prior to preparation of the infusion solution, and the final patient infusion solution in the IV bag or bottle can be stored for up to 24 hours. To reduce microbiological hazard, it is recommended to use as soon as practicable after reconstitution/dilution and if storage is necessary, to hold at 2-8°C.
In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

The lyophilised vials of Caspofungin AN should be stored at 2-8°C, refrigerate, do not freeze.
Reconstituted vials of Caspofungin AN may be stored for one hour prior to preparation of the infusion solution, and the final patient infusion solution in the IV bag or bottle can be stored for up to 24 hours. To reduce microbiological hazard, it is recommended to use as soon as practicable after reconstitution/dilution and if storage is necessary, to hold at 2-8°C.

6.5 Nature and Contents of Container

Caspofungin AN is available in single use glass vials of 50 mg and 70 mg.

Pack size.

1 vial.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical name: 1-[(4R,5S)-5-[(2-aminoethyl) amino]-N2-(10,12-dimethyl-1- oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine] pneumocandin B0 diacetate (salt).
Empirical formula: C52H88N10O15.2C2H4O2.
Formula weight: 1213.42.

Chemical structure.


CAS number.

179463-17-3.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription only Medicine.

Summary Table of Changes